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A Clinical and Scientific Study to Investigate the Influence of Statins on Anastomotic 
Healing in Colorectal Surgery 
 
Anastomotic leak remains one of the most devastating complications of colorectal 
surgery, as it is associated with increased morbidity and mortality, increased need 
for permanent stoma, increased risk of cancer recurrence, prolonged hospital 
admission and increased costs of healthcare. Anastomotic leak represents a failure 
of the complex process of tissue healing, therefore it must be regarded as a 
multifactorial complication, rather than as a single entity. Statins are amongst the 
most widely used drugs in the world, prescribed for the primary and secondary 
prevention of cardiovascular disease. Beyond lipid lowering, statins are known to 
have pleiotropic effects, which may exert a positive influence on processes 
fundamental to wound healing. Preliminary data from clinical studies suggests that 
statins may reduce the incidence of anastomotic leak. 
 
Hypothesis and Aims of this Study 
The hypothesis of this study is that statins promote processes fundamental to 
healthy tissue healing, and may therefore contribute to reducing the risk of 
anastomotic leak following colorectal surgery, and that the post-operative outcomes 
will be improved for patients taking statins. The aims of the study are to investigate 
whether statins exert an influence on colonic tissue healing. This thesis describes two 
studies run in parallel: a scientific study to investigate the effects of statins on 
primary cultured human colonic myofibroblasts, and a clinical study based on 
prospectively collected data from patients undergoing major colorectal surgery. 
 
Outcomes and Conclusions 
Atorvastatin, in concentrations equivalent to therapeutic doses, was shown to 
promote both the metabolic activity, and proliferation of primary cultured colonic 
myofibroblasts. Data was analysed from 113 patients in the clinical study, 38.9% of 
whom were taking statins at the time of the study. No difference was seen in the 
incidence of anastomotic leaks in patients taking statins, compared to those patients 
not taking statins, although the study population represented a relatively small 
cohort of patients with a low incidence of anastomotic leak (6 leaks out of 113 
patients). The outcome from the clinical study raises the possibility that statins may 
represent a form of pharmacological prehabilitation, by normalising the risk of 
anastomotic leak in a population of patients with significant comorbidities, and a 
higher risk of anastomotic leak. The studies described in this thesis suggest that 
statins have an influence of processes fundamental to colonic tissue healing, and may 
contribute to reducing the risk of anastomotic leak. The potential direction for 





Surgery to remove a diseased section of bowel, and form an anastomosis to restore 
intestinal continuity is routinely carried out worldwide, to treat both benign and 
malignant disease. Over the past 200 years, developments in surgical technique, 
understanding of tissue healing, control of sepsis, and developments in anaesthesia 
have converted gastrointestinal anastomosis from a life-threatening procedure, to a 
procedure that is regarded as routine and safe.(1) Despite these improvements, 
impaired healing of the anastomosis, leading to anastomotic leakage (AL), remains 
the most feared complication of colorectal surgery, as it has been shown to increase 
the risk of 30 day mortality, overall mortality(2-5), need for permanent stoma(6, 7), 
impaired anorectal function(8, 9) and impaired quality of life(8, 10). There is also 
considerable evidence to suggest that AL is associated with an increased risk of 
cancer recurrence(3, 5, 11-13), although some authors dispute that observation(14, 
15). Anastomotic leak is suspected to account for a quarter of all post-operative 
deaths following colorectal surgery(16, 17), and is also associated with delay to post-
operative chemotherapy, prolonged hospital admission and increased healthcare 
costs(2). The quoted incidence of AL following colorectal surgery varies widely, with 
modern series reporting incidence of leak ranging from 1.8%-30%(2, 18-20). The wide 
range of reported incidence of leak is due to variations in definition of leak, varied 
approaches to the diagnosis of leak, the nature of the patient population, series 
reporting rectal or low rectal surgery only, and retrospective analysis of data(2, 18). 
As the consequences of anastomotic leak are so serious, there is considerable 
interest in the development of strategies to reduce the incidence of leak. 
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Definition of Anastomotic Leak  
Although anastomotic leak is widely recognised as a serious complication, and is 
widely researched, there is no widely accepted definition; a systematic review of the 
definition of anastomotic leak identified 29 different definitions of anastomotic leak 
in lower gastrointestinal surgery(21). The United Kingdom Surgical Infection Study 
Group proposed “leak of luminal contents from a surgical join between two hollow 
viscera” as a definition(20), however that definition has rarely been referred to and 
the majority of studies refer to clinically relevant observations including peritonitis, 
faeculant discharge, drain discharge, abscess (including pre-sacral abscess), fever, or 
radiological findings in the definition(20). The International Study Group of Rectal 
Cancer published a universal definition: “A defect of the intestinal wall at the 
anastomotic site (including suture and staple lines of neorectal reservoirs) leading to 
a communication between the intra- and extra-luminal compartments.” A clinical 
grading schema to describe the management strategy required following diagnosis 
of leak was published alongside the definition: Grade A leaks: no change to patient 
management required; Grade B: Require intervention, but not re-laparotomy; Grade 
C: require re-laparotomy(22). The definition was validated in a study of 2103(23). 
 
Risk Factors for Anastomotic Leak and the Physiology of Tissue Healing 
Numerous studies have attempted to establish risk factors for anastomotic leak, in 
order to identify risk factors that may be corrected pre-operatively, or to identify 
patients whose risk of anastomotic leak warrants modified surgical strategy. Patients 
regarded as having a high risk of leak may either undergo an operation that does not 
require anastomosis, or may have an anastomosis protected by a proximal, 
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defunctioning stoma. An awareness of factors contributing to a patient’s risk of 
anastomotic leak also offers the advantage of allowing the patient to be involved in 
informed pre-operative decision making(17). Wound healing is a complex process, 
therefore numerous potential reasons for impaired or failed wound healing exist, and 
compromise to any facet of wound healing may lead to failure. Although numerous 
risk factors for colorectal anastomotic leak have been proposed over the past few 
decades, there is considerable conflict in the literature surrounding many of those 
risk factors. Before considering factors that may predispose to impaired anastomotic 
healing, it is necessary to consider the biology of wound healing, and factors that 
contribute to normal tissue healing in the colon.  
 
Acute Wound Healing 
Acute wound healing is described as the highly regulated process of cellular, 
humoural and molecular events activated at the time of injury, resulting in a time-
dependent, orderly pattern of tissue repair(24). The classically described steps of 
wound healing are haemostasis, inflammation, fibroproliferation, and 
remodelling(24); abnormalities in any of those processes may lead to deficient 
healing. If the inflammatory response is delayed, or inadequate, wound 
contamination or infection may ensue, leading to abnormal signalling for progression 
into the fibroproliferative phase of repair – the phase during which wound strength 
increases very rapidly. If the fibroblast response is delayed or inhibited, the 
formation of early scar, and laying-down of provisional matrix will be compromised, 
increasing the duration that the wound is subject to mechanical load, and the length 
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of time that the wound strength is entirely dependent upon the material that has 
been used to bring about tissue apposition(24). 
 
Following clot formation, inflammatory cells migrate to the injured tissue. 
Neutrophils are the first inflammatory cells to reach the wound, and act 
predominantly to sterilise and debride the wound in the early phase. Neutrophils 
have also been shown to enhance wound healing by secreting angiogenic factors 
VEGF, TNF-α and IL-1(25). Monocytes and macrophages then infiltrate the wound. In 
addition to phagocytosing injured tissue, macrophages secrete numerous autocrine 
and paracrine factors. Macrophages have been shown to be the only inflammatory 
cell type that is absolutely required in tissue healing(24). During the acute phase of 
inflammation, the wound essentially has no inherent strength; if this phase is 
prolonged, the chance of wound failure is increased(26).  
 
Fibroblasts migrate into the healing wound within the first day of wounding, and 
proliferate rapidly, under the influence of growth factors, in normal wound healing 
they become the predominant cell type in the healing wound by day 4(25). 
Fibroblasts subsequently secrete collagen and other extracellular matrix (ECM) 
proteins, contributing to the wound ultimately gaining strength(27). During the 
proliferative phase of wound healing, collagen breakdown and synthesis occur 
concurrently, with breakdown predominating over the first 2-3 days; again 
emphasising the wound’s dependence on the material used for the repair during 
early wound healing(17, 28). Wound contraction, another fundamental step in 
wound healing, is also mediated by fibroblast activity, as the fibroblasts attach to, 
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and migrate through early matrix(25). Studies comparing dermal wound healing with 
intestinal wound healing have shown that intestinal anastomoses heal at a much 
greater rate than dermal wounds, and that collagen is produced by both fibroblasts, 
and smooth muscle cells in the bowel(18). 
 
In addition to an understanding of wound healing at the cellular level, it is important 
to consider the anatomy of the bowel in anastomotic healing. The layers of the colon, 
from innermost to outermost, are mucosa, submucosa, muscularis propria and 
serosa; each layer has a role in tissue healing. 
 
Mucosa: The innermost layer of the colon, composed of columnar epithelial cells and 
mucin cells, and openings into crypts of Lieberkühn(29). The crypt bases contain stem 
cells, which mature into epithelial cells as they migrate towards the lumen. The 
lamina propria, between mucosa and muscularis propria harbours immune cells and 
capillaries. Neither the mucosa nor lamina propria contribute strength to the 
anastomosis, however the mucosa’s role in the secretion of mucus, and rapid 
epithelialisation of the wound protect against the considerable bacterial load within 
the colon, thereby preventing wound complications associated with sepsis. The 
lamina propria is a source of vital immune and inflammatory cells(17, 28). 
Submucosa: When considering anastomotic healing the submucosa is the most 
important layer of the bowel; a principle demonstrated by Halsted in 1887, 
describing “the resistance furnished to the needle on entering the submucosa”(1, 18, 
30). The majority of the collagen in the bowel wall is contained within the 
submucosa, type I collagen predominates, although types III and V are also 
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present(17). Cross-linking of collagen is also fundamental to the strength that it 
provides – adequate nutrition and tissue oxygenation are essential for cross-
linking(17, 18). The blood supply to the bowel terminates in the submucosa, forming 
a network of capillaries, to supply the mucosa with nutrients and oxygen(17). 
Muscularis propria: Formed from an inner, circular layer, and outer longitudinal 
layer, the main function of the muscularis propria is peristalsis, rather than strength. 
This layer may become abnormal in disease states such as diverticular disease; the 
number of elastic fibres increases, leading to a thickened, shortened bowel. 
Associated oedema and inflammatory infiltration may also be present in diseased 
bowel. Anastomoses formed using inflamed or diseased bowel are known to be at 
increased risk of leak.(17) 
Serosa: The thin outer layer of the bowel offers little or no strength to the 
anastomosis, but is essential in sealing the anastomosis. It is widely recognised that 
areas of bowel that lose the serosa have a high risk of leak(28). It is likely that the 
serosa seals small defects within the anastomosis, and therefore prevents these 
small defects progressing into defects which leak(17). 
Blood Supply 
It is well recognised that an adequate blood supply is vital to any healing tissue. This 
tenet is especially pertinent to intestinal anastomoses, as major vessels that supply 
the bowel are divided and ligated prior to forming the anastomosis, therefore blood 
supply from the residual vessels must be adequate to perfuse the anastomosis. In 
oncological surgery these vessels are ligated close to their origin, potentially limiting 
blood supply to a large section of bowel. The healing anastomosis requires a blood 
supply sufficient to deliver oxygen, inflammatory cells, nutrients and growth factors. 
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The bowel typically receives 20% of cardiac output, two-thirds of which is diverted to 
the mucosa(31). The mucosa is very sensitive to impaired perfusion, therefore 
susceptible to ischaemia. Ischaemic injury of the mucosa will compromise the 
mucosa’s barrier function, and may progress, leading to full thickness ischaemia. If 
blood supply is restored, following a period of ischaemia, reperfusion injury may be 
more significant than the initial ischaemic insult(31). 
 
Before considering anatomical factors that are relevant to anastomotic perfusion, it 
is also important to recognise that perfusion to the bowel is susceptible to 
compromise as a result of hypoperfusion arising from significant blood loss, 
hyperadrenergic situations (“fight or flight” response) and from cardiogenic 
complications, such as atrial fibrillation. 
 
It is generally well understood that branches of the superior mesenteric artery (SMA) 
supply the jejunum, ileum, caecum, ascending colon and transverse colon, that 
branches of the inferior mesenteric artery (IMA) supply the descending colon, 
sigmoid colon and rectum. The marginal artery of Drummond arises as an 
anastomosis of the terminal branches of the SMA and IMA, this artery may be 
deficient or non-patent in some individuals. The area around the splenic flexure, 
known as Griffith’s point, is regarded as a “water shed” area that is particularly 
susceptible to hypoperfusion during episodes of hypotension. Angiographic studies 
have also shown the proximal descending, and mid-descending colon to have more 
widely spaced, and fewer anastomotic vessels than other parts of the colon(32). The 
IMA is commonly ligated during left sided colonic resections; an area of controversy 
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surrounds preservation of the most proximal branches of that artery. Some authors 
advocate preserving proximal branches, in order to preserve marginal blood supply 
to the residual colon, therefore reduce the risk of leak, whilst others advocate 
ligation of the vessel at its origin to adhere to principles of oncological surgery(33-
36). It is likely that, provided sufficient left sided colon is removed, high tie of the IMA 
is safe, and that leak risk is only increased if a high tie is associated with inadequate 
colonic resection before forming the colorectal anastomosis, although it is also 
suggested that patients at increased risk of atherosclerotic disease may benefit from 
preservation of proximal branches of the IMA(17, 32). 
The Rectum  
The rectum is worthy of special consideration from the point of view of anastomotic 
leaks for a number of reasons. It is widely accepted that anastomoses involving the 
rectum, have a higher risk of leak than ileocolic or colo-colonic anastomoses, and 
that leak risk increases with low rectal anastomosis(18). Serosal coverage is absent 
for the lower two-thirds of the rectum(37), consequently the sealing role provided 
by that layer is absent in low anastomoses. The majority of blood supply to the 
rectum is from the right and left branches of the superior rectal artery, a branch of 
the inferior mesenteric artery. Following ligation of that supply, the rectal stump will 
depend upon the middle rectal artery, a small branch of the internal iliac artery, and 
the inferior rectal artery, a branch of the internal pudendal artery. Angiographic 
studies have shown that the anastomotic blood supply arising from the middle and 
inferior rectal arteries is frequently limited, and that the posterior rectum is 
dependent upon intramural collateral vessels(17, 32, 38). Goligher identified that 
anastomotic dehiscence in rectal anastomoses typically occurred in the posterior 
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aspect of the anastomosis(39); an observation likely to be explained by the nature of 
the blood supply to that area. In addition to the residual blood supply to the rectal 
stump, the colorectal anastomosis derives a blood supply from the segment of 
proximal colon use in the anastomosis. The potentially sub-optimal blood supply to 
the rectal stump emphasises the importance of ensuring good blood supply from the 
proximal end of the anastomosis, and several authors have described techniques to 
ensure that the tissue used in the proximal edge of the anastomosis is well 
vascularised, and under low tension(18, 40). 
 
The oncological management of rectal cancer has been the focus of extensive 
research for several decades, from the point of view of performing oncologically 
sound surgery, and that of performing sphincter-preserving surgery. As discussed 
previously, surgery to remove low rectal tumours, but preserve the sphincter 
complex, is associated with increased leak risk due to low rectal anatomy. The other 
significant advances in the management of rectal cancer that have had a significant 
influence on the study of colorectal anastomotic leak are total mesorectal excision 
and neo-adjuvant (pre-operative) therapy. 
 
In 1982, having identified that the rectum and mesorectum had a common 
embryological origin, Heald introduced the concept of total mesorectal excision 
(TME)(41). The technique of TME involves sharp en bloc dissection of the tumour and 
its surrounding mesorectal tissue, with dissection in the avascular plane between the 
mesorectum and surrounding tissue. The technique had the advantage of 
incorporating the lymphatic drainage of the rectum into the resected specimen and 
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has been shown to confer increased disease free survival and significantly reduced 
local recurrence of tumour(42). TME has been widely adopted by colorectal 
surgeons, however in its early days the reported leak rates reached approximately 
23% before returning to pre-TME era rates as surgical techniques improved to modify 
the leak risk (17, 43). 
Adjuvant and Neo-Adjuvant Therapy 
As the rectum is confined within the pelvis, rectal tumours are amenable to 
treatment with radiotherapy. Numerous studies over the past three to four decades 
have investigated the role of radiotherapy, and chemotherapy in the management 
of rectal cancer. The neo-adjuvant management of rectal cancer is one of the most 
keenly debated subjects in surgical oncology, and has been the focus of numerous 
clinical trials. Although opinions differ regarding the optimal pre-operative 
management of rectal cancer, many rectal cancer patients undergo pre-operative 
radiotherapy, which may be combined with chemotherapy. The effect of neo-
adjuvant therapy upon leak will be discussed later in this document. 
 
As the management of rectal cancer is such an intensively researched area, there is 
a vast amount of data relating to patients who have undergone treatment for rectal 
cancer. Data is sourced from prospectively managed registries, or from formal clinical 
trials. In addition to cancer-specific outcomes, data regarding post-operative 
complications is collected, therefore much of the data surrounding anastomotic leak 
is from multivariate analyses of such databases, rather than from prospective trials 
designed to investigate anastomotic leak specifically, and pertains to rectal 
anastomoses, rather than colonic anastomoses. As a consequence of the 
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heterogeneity of the data, the list of proposed risk factors is extensive, and there is 
conflict of opinion surrounding several of the identified risk factors. 
Identified Risk Factors 
It is appropriate to consider categories for anastomotic leak risk, as this approach 
may help to identify risk factors that may be modified pre-operatively, in order to 
reduce the risk of leak or may justify an operative strategy to reduce the risk of leak, 
or mitigate against the consequences of leak. The categories to consider are: 
anatomical, patient-specific, and perioperative. 
Anatomical risk factors 
The location of the anastomosis is well recognised as an influence on risk of leak; the 
more distal the anastomosis, the higher the risk of leak. Based on recent published 
series, the quoted risk of leak following ileocolic anastomosis is 2-3%, up to 10% for 
left sided resections, and up to 17% for low rectal anastomoses(5, 17). The increased 
risk of leak associated with left sided and low rectal anastomoses is likely to be due 
to the potential compromise to blood supply, and lack of peritoneal covering of the 
low rectum, as previously described. The increased volume of colonic bacteria, from 
proximal to distal colon, has also been proposed as an explanation of increased 
frequency of leak in operations involving the left side of the colon(9). 
Patient-Specific Risk Factors 
Several patient-related risk factors have been proposed, but again, many of these are 
the subject of conflicting opinion. Factors including tobacco use and high alcohol 
intake have been shown to increase leak risk in some studies,(20, 44, 45) numerous 
however other studies have failed to reproduce those findings, so these risk factors 
are only weakly associated with leak risk(17). Obesity and male gender have both 
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been associated with an increased leak risk in left-sided and rectal resections, but 
not in right sided resections(2, 46, 47). Isolating risk factors in cohorts of complex 
patients, who may have multiple risk factors, is particularly challenging, moreover it 
is likely that having multiple risk factors, presents a greater risk of leak. An American 
Society of Anaesthesia (ASA) score of 3 or more, or a Charlson Comorbidity Index 
(CCI) score of 3 or more are consistently shown to be associated with increased leak 
risk(17, 20). 
Underlying Disease 
The importance of forming an anastomosis with healthy tissue has been recognised 
for many decades(18). The majority of colorectal resections, particularly rectal 
resections, are carried out to manage malignant or potentially malignant disease, 
and in that situation the sites of transection of bowel are determined by principles 
of oncological surgery, which should ensure healthy tissue. Consideration of healthy 
tissue is particularly relevant when operating on patients with inflammatory bowel 
disease, or diverticular disease. Anastomoses in patients with Crohn’s disease should 
be formed with macroscopically normal tissue, however it is not necessary to exclude 
Crohn’s at the microscopic level before forming an anastomosis(48). In bowel 
affected by diverticular disease, both the longitudinal and circular muscle layers 
become abnormal. An increase in elastic fibres in the longitudinal layer results in 
thickening and relative shortening of the bowel, and the thickness of the circular 
layer becomes greater due to being in a chronically contractile state(49). It is also 
common for chronically inflamed tissue to have associated oedema. Macroscopic 
changes of diverticular disease – outpouches caused by herniation of the mucosa 
through the muscularis propria – may also lead to areas of weakness and potential 
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defects in the anastomosis. Sub-optimal healing, predisposing to anastomotic leak, 
is much more likely in thickened, oedematous tissue, or tissue with macroscopic 
defects, therefore bowel affected by diverticular disease should not be used in 
anastomoses(17). 
Nutrition 
The importance of nutrition in wound healing has been described above, so it is 
logical that malnutrition is associated with impaired wound healing. Poor nutritional 
status tends to be defined as weight loss ≥10% of body weight over the previous 3 
months, serum albumin <35g/L, and serum total protein <55g/L. Malnutrition is 
widely accepted to be a risk factor for increased risk of post-operative morbidity and 
mortality(50), and has been shown to be associated with anastomotic leak following 
colonic resections, specifically right-sided colonic resections(17). 
Medications 
The effect of corticosteroids is especially relevant to the management of patients 
with inflammatory bowel disease, who have been treated medically, prior to 
undergoing surgery. Corticosteroids may compromise wound repair by inhibiting 
cellular signalling that promotes activation and migration of inflammatory cells, and 
by inhibiting collagen synthesis and wound contraction(27). It is therefore plausible 
that steroids should be regarded as a risk factor for anastomotic leak. A collection of 
retrospective studies failed to demonstrate an increased leak risk in association with 
steroids, however a recent prospectively designed study showed a convincing leak 
risk in association with both perioperative, and long-term corticosteroid use(17, 51). 
Non-steroidal anti-inflammatories (NSAIDs) have also been investigated as a 
potential risk factor for anastomotic leak; this is particularly relevant in the era of 
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enhanced recovery after surgery (ERAS), as NSAIDs are commonly used to avoid the 
need for opiate analgesia. A recent review of the risk of NSAIDs concluded that this 
class of drug does not increase the risk of anastomotic leak(52). 
Neoadjuvant Therapy 
Pre-operative radiotherapy, or chemoradiotherapy with 5-Fluorouracil (5-FU) or its 
oral pro-drug capecitabine, has become the standard of care for locally advanced 
rectal cancer, with the aim of reducing the risk of local recurrence. There are 
considerable variations in pre-operative regimes, and a review of that field is outside 
of the scope of this study. The effects of radiation, which may compromise tissue 
healing, include mucus depletion, increased apoptosis, expression and activation of 
proinflammatory cytokines, vascular injury, and activation of the coagulation 
cascade(53). Anatomical tissue planes may also lose their distinction as a result of 
radiation-induced injury, compromising TME surgery and post-operative 
haemostasis. Radiotherapy was widely accepted as a risk factor for anastomotic leak, 
possibly based on a study which demonstrated an association between previous 
abdominal or pelvic radiotherapy and anastomotic leak(16), however further studies, 
including a study investigating the effect over 30 years, did not find pre-operative 
radiotherapy to be an independent risk factor for leak(54). There is considerable 
conflict within the current literature regarding neo-adjuvant radiotherapy alone as a 
risk factor for anastomotic leak, however, the chance that it contributes to leak, 
particularly in the presence of other risk factors does remain(9, 17). 5-FU is known to 
affect cell proliferation, promote cell-cycle arrest and apoptosis, and may cause 
significant cytoskeletal abnormalities, and has been shown to inhibit fibroblast 
proliferation and collagen secretion in vitro, and has been shown to impair 
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experimental anastomotic healing in the rat(55-57). Side-effects of 5-FU include 
gastrointestinal disturbance, in addition to systemic effects such as nausea and loss 
of appetite, which may contribute to impaired tissue healing and impaired nutritional 
state pre-operatively. A randomised multicentre phase 2 trial, investigating the 
addition of panitumumab, an anti-epidermal growth factor receptor, compared to a 
standard capecitabine based chemoradiotherapy regime, showed a leak rate of 15% 
in the panitumumab group, compared to 4% in the capecitabine only group(58). It is 
likely that the effect of pre-operative systemic chemotherapy will become 
increasingly relevant to the risk of post-operative complications, as new agents are 




Prolonged operative time has been shown to be associated with increased incidence 
of anastomotic leak. The significance of that measure is contentious, as it could be a 
marker of a more challenging operation, such as removal of a large tumour, or 
operating deep in a male pelvis. From a clinical point of view, the benefit of 
recognising prolonged operative time as a risk for anastomotic leak, is that the 
surgeon is more likely to protect the anastomosis, and mitigate for consequences of 
leak, by forming a defunctioning stoma(17). Intra-operative blood loss has also been 
identified as an independent risk factor for anastomotic leak. Some studies quote the 
requirement of transfusion as a marker of leak risk, although the judgement 
surrounding need for transfusion is a relatively subjective measure, and might be a 
marker of complicated surgery, or poor surgical technique(17, 47). A review of 4340 
 21 
cases showed blood loss of over 300ml to be a significant risk factor for anastomotic 
leak(59). 
Other perioperative factors shown to increase leak risk include pre-operative 
diastolic blood pressure over 90mmHg, hypotension, oxygen saturation below 90% 
for over 5 minutes(35, 60) and administration of more than 8000ml of intravenous 
fluid (IV) over the 72 hour perioperative period(61). Excessive fluid administration is 
likely to lead to impaired tissue perfusion, and may also promote tissue oedema, 
both of which would compromise wound healing. 
 
Surgical Technique and Surgical Instruments 
Changes or modifications to surgical techniques are assessed for influence on 
multiple outcome measures, including anastomotic leak. Technological 
developments in colorectal surgery which have been investigated for influence upon 
leak, include the use of stapling devices to form the anastomosis (compared to hand-
sewn anastomosis), and the increasing uptake of laparoscopic surgery, compared to 
open surgery. Anastomotic technique – hand-sewn versus stapled - has been 
evaluated in two Cochrane reviews, one review demonstrated no advantage of either 
technique over the other, whist a review considering ileocolic anastomoses 
specifically, demonstrated superiority of stapled anastomoses over hand sewn 
anastomoses(62, 63).   Evidence from the early era of laparoscopic surgery indicates 
that laparoscopic surgery was associated with an increased risk of leak. That 
observation may be reflective of a learning curve, as more recent data shows a 
favourable comparison for laparoscopic surgery compared to open surgery(17, 64, 
65).  One specific consideration relevant to stapled anastomoses in laparoscopic 
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rectal surgery is the observation that 3 or more firings of the stapler, when dividing 
the rectum, was associated with increased leak risk in 2 studies(66, 67). 
 
Colorectal anastomoses may be protected by forming a defunctioning stoma, 
typically a loop stoma, which may be a colostomy or an ileostomy, proximal to the 
anastomosis. The stoma should be reversed, to restore intestinal continuity, 
following investigations to confirm that the anastomosis is both intact, and has not 
strictured, and that the patient is fit for surgery. The rationale behind forming a 
defunctioning stoma to divert the faecal stream is that the consequences of 
anastomotic leak will be mitigated, and that the leak may be managed without the 
need for further major surgery, and that the anastomosis may ultimately be 
preserved. It is important to acknowledge that the formation, and subsequent 
reversal, of defunctioning stomas carries risks of morbidity and mortality(68), and 
that the presence of a stoma is associated with reduced quality of life(69), therefore 
the patient’s risk of anastomotic leak is taken into account before making the 
decision to form a defunctioning stoma(20, 69). In addition to conferring benefit in 
the management of leaks, a number of studies have suggested that the incidence of 
leak is reduced by the presence of a defunctioning stoma(70-72), whilst other studies 
dispute that finding. The difficulty of isolating risk factors for anastomotic leak has 
already been discussed; the majority of the studies reporting the role of a 
defunctioning stoma are retrospective, and it is not always easy to establish whether 
the patients had similar levels of underlying risk for leak. A Cochrane review of 6 
prospectively conducted trials, designed specifically to investigate the influence of 
defunctioning stoma on leak rate, concluded that a defunctioning stoma does reduce 
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the risk of leak, and the risk of needing further major surgery if a leak does occur(73). 
On balance, there is sufficient evidence to support a role for defunctioning stomas in 
the prevention of leak following anterior resection, particularly low anterior 
resection. 
Intra-operative Assessment of the Anastomosis 
Intra-operative testing of anastomotic integrity, followed by operative steps to 
manage signs of an unsound anastomosis, is widely endorsed. Strategies to deal with 
signs of compromised anastomosis include reinforcing the anastomosis with sutures, 
taking the anastomosis down, and refashioning it, forming a proximal stoma to 
defunction the distal bowel, or forming an end stoma instead of a primary 
anastomosis. Options for intra-operative anastomotic assessment fall into three 
categories: simple mechanical assessment, such as an air leak test; endoscopic 
assessment to visualise the anastomosis; and techniques to assess microperfusion to 
the tissue involved in the anastomosis. Leak-testing the anastomosis, particularly 
following a left sided colonic or rectal resection, is carried out by filling the pelvis with 
sterile saline, occluding the bowel proximal to the anastomosis, and gently 
introducing air into the rectum to inflate the perianastomotic bowel. Discharge of 
bubbles of gas indicates that the anastomosis is not sound. Intra-operative leak 
testing of the anastomosis, and acting appropriately if signs of leak are detected, has 
been shown to reduce the rate of leak risk in a number of studies(17, 74, 75). As 
incorporating an air leak test into the operation is a straightforward manoeuvre, and 
has been shown to identify deficient anastomoses, it is reasonable to suggest that 
leak testing should be routine practice, and does not require further investigation.  
 24 
Endoscopic intraoperative inspection of the anastomosis with a flexible 
sigmoidoscope, allows direct visualisation of the anastomosis. Air leak testing is 
incorporated into endoscopic assessment, and this approach has been shown to be 
associated with a low anastomotic leak rate of 2.1%, in a study population of 415 
patients, however that study did not have a control group(76). 
 
Recognition and Management of Anastomotic Leak 
Despite recognition of risk factors, and attempts to reduce leak rate by modifying as 
many risk factors as possible, anastomotic leak is accepted as an inevitable 
complication of colorectal surgery. Prompt recognition of anastomotic leak is 
essential, in order to minimise the clinical consequences of leak, prevent mortality 
and has the advantage of presenting options to manage the leak in the least invasive 
manner(6, 18). A high index of suspicion, supported by clinical observations, is 
essential in the diagnosis of leak; a number of authors have attempted to identify 
markers of leak to facilitate early diagnosis. Serum white blood cell count (WCC), 
serum C-reactive protein (CRP) and serum procalcitonin have all been investigated 
as potential markers for early identification of anastomotic leak(74, 77-81). In 
general, these markers tend to be significantly elevated in patients who have 
developed anastomotic leak, compared to those patients with a sound anastomosis, 
however, as the serum levels of the markers in question tend to rise with 
inflammatory or infective processes with causes other than anastomotic leak, an 
elevated level of any of the serum markers tends to lack specificity for leak. Even 
though the markers are shown to have a high sensitivity for anastomotic leak, their 
low specificity results in a low positive predictive value, therefore a normal or low 
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value may offer reassurance, and a high value may alert the clinician to the possibility 
of leak that should be investigated clinically or radiologically, but does not confirm 
the presence of leak. den Dulk and colleagues have attempted to create a 
standardised clinical tool, the DULK (Dutch leakage) score, derived from a 
combination of clinical observations and values of biomarkers, to increase the 
accuracy of the use of clinical signs and investigation results in the diagnosis of leak 
in its early stage(77, 78). Despite demonstrating impressive sensitivity, the DULK and 
modified DULK scores are compromised by a low positive predictive value. The use 
of such a scoring system does highlight the need for clinicians to “actively seek the 
leak”(78) and has the advantage of adding continuity to the monitoring of patients 
who are likely to be assessed by a variety of healthcare professionals during a 
hospital admission. 
 
Assessment of levels of inflammatory markers in peritoneal drain fluid has also been 
investigated as a method of early detection of anastomotic leak. Markers that have 
been assessed include CRP, lipopolysaccharide binding protein (LBP), procalcitonin, 
interleukins 1, 6 and 10, tumour necrosis factor-α (TNF- α), matrix 
metalloproteinases (MMP) 8 and 9, and E. faecalis(74, 82-86). Assessment of 
peritoneal or pelvic fluid currently remains within experimental realms, however, the 
results of investigations into MMP and interleukin assays show elevated levels of 
these markers in patients who progressed to leak, indicating potential for future 
integration into clinical practice(74). The study to investigate concentration of E. 
faecalis in drain fluid showed that an increase in concentration was significantly 
associated with anastomotic leak, however, the high number of false positive tests 
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resulted in a positive predictive value of 30.2%(84). There is an obvious appeal to 
monitoring drain fluid for markers of anastomotic leak, however, as there is no 
proven benefit for the use of drains to either predict or prevent leak, routine 
drainage following colorectal surgery is not advocated, especially within ERAS 
protocols(86-88). Many experts would view routine drainage as a retrograde step, 
and would not support routine drainage simply to monitor fluid, often for several 
days. 
Strategies to Prevent Anastomotic Leak 
Although significant debate surrounds many of the previously discussed risk factors 
when considered in isolation, it is likely that there is an additive effect of risk factors, 
such that the more risk factors an individual has, the greater the risk of anastomotic 
leak. The majority of strategies to prevent, or minimise the incidence of leak are 
based upon modification of as many risk factors as possible. In reference to the risk 
factors already discussed, approaches to modify risk factors include smoking 
cessation, pre-operative nutritional support and correction of pre-operative 
anaemia. Factors under control of the surgeon include minimising blood loss, forming 
the anastomosis under low tension having ensured healthy tissue with an adequate 
blood supply, goal directed fluid therapy, assiduous technique and air leak testing, 
and decision to form a defunctioning stoma. 
Biotechnology 
Strategies to reduce anastomotic leak by incorporating additional elements to 
established perioperative and intra-operative practice remain reasonably 
uncommon. The role of biotechnology within medicine and surgery is increasing; the 
aim is to develop materials and devices to support and promoting tissue healing. 
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Attempts have been made to identify materials to reduce anastomotic leak, however 
these products remain within the developmental or experimental phase. 
Bioabsorbable Seamgaurd (BSG), a synthetic bioabsorbable staple line reinforcement 
for circular stapled anastomoses, has been investigated by a number of groups over 
the past few years. Results from early studies showed that the device was feasible 
and safe to use(89), however two recent randomised controlled trials (RCTs), with 
302 and 258 patients respectively, failed to show any reduction of anastomotic leak 
in association with the staple line reinforcement(90, 91). The C-Seal is a thin-walled 
biodegradable sheath, incorporated into the lumen of the colon at the time of the 
anastomosis(92). The device protects the intraluminal aspect of the anastomosis, 
and to prevent faecal contamination of the peritoneal cavity, should leak occur. The 
C-Seal has been shown to be a safe and feasible option, however conclusive data to 
determine its efficacy is currently lacking, but should be provided when the results 
of a prospective multicentre trial, aiming to recruit 616 patients reports(93). 
 
The Microbiome and Its Role in Anastomotic Healing and Anastomotic Leak 
The gut microbiome is defined as the collected microorganisms, and their associated 
genetic material, contained within the gastrointestinal tract. Research into the 
gastrointestinal microbiome, and its influence on anastomotic healing, and therefore 
anastomotic leak, represents some of the most important recent work in this field. 
Some of the most influential work has been carried out by John Alverdy and 
colleagues(94). A comprehensive review of the gut microbiome and anastomotic leak 
is beyond the scope of this study; the most pertinent points are that certain 
microorganisms, specifically collagenase producing Enterococcus faecalis, are 
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significantly implicated in the pathophysiology of anastomotic leak(95). Establishing 
the principle that certain microorganisms act as drivers of leak has generated the 
proposal that manipulating the gut microbiome, either with antibiotics or a modified 
diet, may lead to a reduced risk of anastomotic leak(96). Patients with bowel disease 
are subject to a wide variety of factors that may influence the microbiome, including 
dietary restrictions, and the effects of medications including chemotherapeutic 
agents and immunosuppressive drugs. The relationship between the gut 
microbiome, its influence on tissue healing and surgical complications, and methods 
to manipulate the microbiome is likely to remain one of the most prominent areas 
of gastrointestinal surgical research for years to come. 
 
Antibiotics represent one of the most accessible approaches to microbiome 
manipulation. The debate surrounding the role of pre-operative bowel preparation 
using antibiotics, and/or mechanical bowel preparation (MOABP), with the aim of 
reducing infective complications of surgery, pre-dates microbiome-focused research 
by several decades. Consequently, considerable variance exists in the advice issued 
by national and international surgical societies throughout the world. Currently, 
there is a trend toward the use of MOABP in North America, but much less support 
for this approach in Europe. This author has made a significant contribution to a 
recent publication outlining the rationale, and the arguments for and against for the 
use of pre-operative MOABP(97). It is likely that with increased understanding of the 
microbiome, its role in infective complications of surgery, and how it may be 
modified with the use of medications and diet, the role of antibiotics will become 
clearer(98). It may also be the case that other widely prescribed drugs, such as statins 
 29 
(see below), and proton pump inhibitors (PPIs) may be found to influence the 
microbiome, and therefore influence tissue healing and post-operative outcomes. 
 
Potential for Systemic Strategies to Promote Anastomotic Healing 
Systemic effects of malnutrition, steroids and chemotherapy are recognised as 
having potential to impair healing however, to date, no systemic agents that actively 
promote healing have been identified. An interesting observation in a 2012 study by 
Singh et al. introduced the possibility that statins might be associated with a reduced 
risk of anastomotic leak following colorectal surgery(99). In a retrospective analysis 
of 269 patients, 86 of whom were taking a statin pre-operatively, the anastomotic 
leak rate was 1% in the statin group, compared to 7% in the group not taking statins. 
This observation is particularly significant, considering that patients who were taking 
statins had greater baseline perioperative risks, and therefore had a higher risk of 
anastomotic leak. The findings of this study have to be interpreted with some 
caution, as this was a retrospective study, designed to look at the overall effect of 
statins on a collection of markers in patients undergoing elective colectomy, and was 
not designed specifically to assess the effect of statins upon leak. The method of the 
study did not assess daily dose of statin, nor did the study assess patients’ compliance 
with the medications. A more recent North American study, with data from a large, 
prospectively maintained surgical quality improvement collaborative investigated 
the relationship between pre-operative statin therapy and infectious complications 
of colorectal surgery(100). In this analysis of 7285 patients, of whom 34.5% were 
taking statins pre-operatively, there was a significantly lower incidence of post-
operative sepsis, and a significantly reduced rate of anastomotic leaks following 
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rectal resections. As observed in the Singh et al study, the patients who were taking 
statins in this study were also significantly more likely to have comorbidities, and 
therefore a carry higher risk of post-operative complications, making the finding of a 
reduced incidence of infectious complications more noteworthy. Conflicting data has 
come from a more recent retrospective study, designed to investigate the 
relationship between statins and anastomotic leak risk, reported findings from 2766 
patients, 19% of whom were prescribed statins perioperatively. The study identified 
specific statins, and prescribed dosages, and reported that patients prescribed 
statins perioperatively did not have a significantly different leak risk from those 
patients not taking a statin(101). All of these studies are compromised by 
retrospective methodology, and by differing definitions of leak, as the 2 studies 
demonstrating a beneficial effect of statins study included clinically or radiologically 
diagnosed leaks, whereas the second study considered only clinically significant 
leaks. The authors of the study that showed no significant difference also state that 
as the patients were not matched, it is possible that statins were normalising the risk 
of patients with an overall higher preoperative risk of leak(101). In the two studies 
that showed a reduced incidence of leak, 32% and 34.5% of patients respectively, 
were taking statins, compared to 19% of patients in the study that showed no 
difference, therefore differences in statin prescribing protocols may contribute 
towards the conflicting findings. Despite the compromises of the studies that 
reported a potentially protective effect of statins, such an observation warrants 
further investigation, especially as statins are used so prevalently throughout the 
developed world, and have been shown to have effects upon tissue healing in both 
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animal and human studies. The investigation of the effects of statins on colonic 
healing is the primary focus of the experimental work described in this study. 
Statins 
3-hydroxy-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitors, commonly 
referred to as statins, inhibit the conversion of HMG CoA to mevalonate, which 
subsequently inhibits the synthesis of a number of isoprenoids vital for cellular 
functions. The most well-recognised effect of inhibition of mevalonate synthesis is a 
reduction in synthesis of cholesterol(102). Statins are widely prescribed throughout 
the developed world, as they have been robustly demonstrated to reduce the 
incidence of cardiovascular disease(103). As hypercholesterolaemia is strongly 
associated with the risk of cardiovascular disease, it was initially believed that the 
beneficial effects conferred by statins were entirely due to reducing synthesis of 
cholesterol, particularly low density lipoprotein (LDL). Pleiotropic effects of a drug 
are the observed effects of the drug, beyond those for which the drug was initially 
intended. It is widely accepted that statins have a number of effects independent of 
their lipid lowering action. The pleiotropic effects of statins include stabilisation of 
endothelial function, decreased smooth muscle proliferation, and reduced vascular 
inflammation; effects which are widely believed to contribute to the demonstrated 
reduction in cardiovascular disease in patients who take statins(103-106)(Fig 1). 
Several of the pleiotropic effects of statins affect processes related to tissue healing; 
it is therefore plausible that statins may influence colonic tissue healing, and 




Figure 1: The mevalonate pathway and consequences of inhibition of mevalonate synthesis. Reproduced with 





The effect of statins on cells fundamental to tissue healing 
 
Fibroblasts 
As outlined earlier in this document, fibroblasts are fundamental to tissue healing, as 
they migrate into the wound then proliferate, under the influence of soluble growth 
factors and cytokines. Fibroblasts secrete proteins that form the provisional matrix, 
which is subsequently remodelled as the wound heals. The regulation of fibroblast 
proliferation, migration, and secretory function is crucial to tissue healing; 
insufficiency of those factors may result in failed wound repair, whilst excessive 
function may lead to fibrosis. Statins have been shown to affect the proliferation and 
migration of cardiac fibroblasts, leading to beneficial effects upon remodelling of 
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cardiac tissue(106). Statins have also been shown to reduce fibroblast adhesion, 
migration and viability of cardiac fibroblasts in vitro(107). Statins have also been 
shown to have effects upon the function of human lung fibroblasts, specifically 
inhibiting the secretion of matrix metalloproteinases (MMPs), proteolytic enzymes 
fundamental to tissue repair and remodelling(108). Although significant research has 
been conducted on fibroblasts derived from cardiac and pulmonary tissue, the 
effects of statins upon fibroblasts derived from bowel tissue have not yet been 
investigated, as suggestions that statins may affect tissue healing in the bowel have 
only been made relatively recently (99). One of the aims of this project is to 
investigate the effect of statins upon proliferation and function of fibroblasts derived 
from human colonic tissue. 
The Effect of Statins upon Angiogenesis and Endothelium 
The effects of statins upon angiogenesis have been extensively investigated, 
although none of the studies to date has been carried out on tissue derived from 
colon. A study on the effect of simvastatin upon proliferation, migration, sprouting 
and tubulogenesis, in microvascular endothelial cells derived from bovine retina 
demonstrated a biphasic effect on all of the observed outcomes, such that low doses 
promoted pro-angiogenic outcomes, whilst higher doses were found to be inhibitory 
with regard to angiogenesis, and the highest doses induced cell death in vitro(109). 
Atorvastatin has been shown to influence the angiogenic behaviour of human 
umbilical vein cells (HUVEC) with the same effect, such that low dose Atorvastatin 
promoted HUVEC cell migration and tube formation, but inhibited those features at 
higher doses(110). Both systemically administered and topically applied statins have 
also been shown to promote wound healing by enhancing angiogenesis in 
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experimental wounds in mice(111, 112). The biphasic effect on angiogenesis has also 
been demonstrated in liver regeneration in an experimental rat model(113). It is 
entirely plausible that statins would influence endothelial cell behaviour, and 




To date, there are no reported studies describing the effects of statins upon human 
colonic tissue, from the point of view of wound healing, however a small number of 
animal studies have been reported. Statins have been shown to strengthen colorectal 
anastomotic wound healing in the rat, however tissue healing in the rat colon does 
not necessarily a provide a reliable model for the human colon, as anastomoses in 
the rat are much less prone to leak, even under experimental conditions specifically 
designed to induce anastomotic leak(114-116). 
The rationale for the studies described in this thesis. 
The only current evidence to indicate that statins may reduce the risk of anastomotic 
leak following colorectal surgery is from retrospective clinical studies. The recognised 
pleiotropic effects of statins, and their observed effects upon both cells and 
processes fundamental to tissue healing, make it plausible that statins could 
influence colonic tissue healing. As statins are amongst the most widely used 
medications in the developed world, and are generally well tolerated, promoting 
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tissue healing, thereby reducing the incidence of such a devastating complication as 
anastomotic leak, would be of considerable value. 
 
The hypothesis of this study is that statins promote processes fundamental to 
healthy tissue healing, and may therefore contribute to reducing the risk of 
anastomotic leak following colorectal surgery, and that the post-operative outcomes 
will be different for patients taking statins.  
This thesis presents two studies carried out in parallel. The first study was a 
laboratory-based study to harvest and culture myofibroblasts from human colonic 
tissue, and then to carry out experiments to investigate the effects of statins upon 
those cells. The second study was a clinically based study, using prospectively 
collected data from a cohort of patients undergoing major colorectal surgery in an 
inner-city university hospital, to establish whether there was a relationship between 


























Protocol for Tissue Preparation and Primary Cell Culture. 
The method described below was used to culture the cells used for the experiments 
described later in the study. Over the course of the study, tissue was acquired from 
approximately 30 patients. Initially, the process was refined and developed, before 
cell lines were established from 5 patients using the method described below. 
A full thickness section of fresh colon, of approximately 2cm in length, was acquired 
at time of operation, immediately after the specimen was delivered from the 
abdomen. The specimen was taken from the resection margin furthest from the 
diseased area of bowel, and therefore not required for histopathological assessment. 
Fat, mesenteric tissue and epiploica were dissected from the specimen in theatre. 
Macroscopic contamination was removed with a gauze swab, and the specimen was 
placed into ice cold phosphate buffered saline (PBS) with antibiotics (Penicillin, 
Streptomycin, Amphotericin B), and transferred to the laboratory. Specimens for cell 
culture were taken from patients who had no history of having taken statins. 
 
The tissue underwent multiple washings in PBS with antibiotics, until the tissue was 
macroscopically free of any colonic content, and the effluent was also completely 
free of colonic content other than stray epithelial cells. 
 
The specimen was placed into 70% ethanol for 3-5 seconds, then rinsed in fresh PBS 
3 times, for 30 seconds per rinse. 
 




Homogenised tissue was transferred into 50ml test tubes (3g per tube). 20 ml of 
collagenase II (Sigma-Aldrich; 5ml Collagenase, 15 ml PBS) was added to each test 
tube, and the test tubes were placed onto a rotating mixer, at 37°C, for 90 minutes. 
 
Following incubation, the homogenised tissue was filtered through a 70m cell 
strainer. The filtered fluid was centrifuged at 2000 rpm for 7 minutes, then the 
supernatant was aspirated and discarded. 
 
Cell culture medium DMEM GlutaMax + (Gibco, Life Technologies), supplemented 
with 50ml of foetal calf serum per 500ml medium) was prepared. This medium was 
used for all of the myofibroblast based experiments. No additional antibiotics were 
added to this medium. 
 
The cell pellet was suspended in 2 ml of culture medium DMEM+ GlutaMax (Gibco, 
Life Technologies), and vortexed. 14mls of the same medium were added to the test 
tube, which was mixed with a vortex machine for 5 seconds. Falcon T25 flasks were 
prepared with attachment factor (Sigma-Aldrich attachment factor solution).  
 
The suspended cells were then transferred into the Falcon T25 flasks (4ml per flask). 
The flasks were incubated at 37°C, 5% CO2 for 24 hours. Following microscopic 
confirmation of cell adherence to the base of the flask, the medium was aspirated, 
the cells were washed 3 times with PBS, and 4mls of fresh medium was applied. 
Isolated cells were confirmed as myofibroblasts by typical appearance under light 
microscopy, cell staining (see below) and by flow cytometry (data not available due 
to failure of now obsolete equipment). 
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Passaging of cells 
 
Aseptic precautions were maintained throughout. 
Cells were maintained in plasma treated tissue culture polystyrene flasks; typically, 
Falcon T75 (Scientific Laboratory Supplies, UK). Cell culture medium was aspirated 
from the tissue culture flask, and resultant adherent cells washed 3 times with PBS 
to remove senesced cells and residual serum proteins to prevent compromised 
trypsinisation. 
After washing, a solution of 5g porcine trypsin, 2g EDTA in 100mL of 0.9% sodium 
chloride (Sigma-Aldrich, UK) diluted to a working concentration of 10% (v/v) using 
PBS was applied to the adherent cells. Trypsinisation was conducted at 37oC for 5-10 
minutes until approximately 75% of cells had detached from the base of the flask, 
confirmed by transmitted light microscopy. The suspension of cells and trypsin was 
diluted in an equal volume of cell culture medium, pre-warmed to 37oC, containing 
5% Foetal calf serum (v/v) (Lonza, % (v/v) to inhibit the trypsinisation reaction and 
therefore prevent protease induced cell damage during subsequent steps.  
The diluted trypsin and cell suspension was centrifuged at 1.5x103 rpm for 6 minutes 
at 4oC to retrieve the cells. The supernatant was aspirated and the cell pellet was 
then resuspended in an appropriate volume of cell culture medium. Long term cell 
culture was facilitated by distributing the solution into the appropriate number of 
tissue culture vessels and diluting the suspension in a defined volume of cell culture 
medium. All cells were reseeded at 1/3 of the confluent cell density and incubated at 
37oC, in a humidified, 5%CO2 environment. Culture medium was replaced every 3rd 
or 4th day by aspiration of used medium and introduction of fresh cell culture 
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medium, pre-warmed to 37oC. The culture flasks were monitored regularly by 
transmitted light microscopy. When a confluent monolayer was confirmed, the 
passaging process was repeated in a 1:3 split. 
 
Cell Culture Medium Containing Statin 
 
Atorvastatin stock solution was created by dissolving 25mg of Atorvastatin calcium 
salt trihydrate (Sigma-Aldrich) in 2.5ml of dimethyl sulfoxide (DMSO) to give a 
0.0165M stock solution of Atorvastatin, in accordance with manufacturer’s 
instructions. The stock solution was then diluted appropriately to give a range of 
concentrations of Atorvastatin in culture medium. The concentrations created were 
0.01µM, 0.1µM, 1µM, 10µM, 20µM to ensure a range that included accepted sub-
therapeutic and supra-therapeutic serum equivalents(117). Cell culture media for 
control arms included DMEM GlutaMax+ with no statin, DMEM GlutaMax+ with 
DMSO only at the 10µM equivalent concentration (referred to as vehicle), and DMEM 




3rd passage cells, cultured from a single donor, and maintained as described above, 
were used for the entire experiment. Confluent monolayers of cells in all T75 Falcon 
flasks were confirmed using phase contrast transmitted light inverted microscopy. 
Used medium was aspirated and cells were washed 3 times with PBS before being 
detached with trypsin as described above. Following detachment, cells were 
resuspended in 5ml medium to each flask, and flasks were inspected under phase 
contrast light microscopy to ensure that all cells were washed from the flask. The 
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suspension of detached cells was transferred to a 15ml Falcon tube and centrifuged 
for 5 mins at 1500 rpm at 4C. Supernatant was aspirated. Cells were resuspended in 
1ml of medium, and counted using a haemocytometer. 
Cell suspensions were created, and cells were transferred to 24 well plates to 
populate wells with 2500 cells per well for the low seeding group, and 15000 cells 
per well for the high seeding group. The rationale behind the low seeding and high 
seeding groups was that cells in the low seeded wells would be unlikely to be limited 
by contact inhibition, and would be able to divide and metabolise rapidly. All cells 
were initially seeded in DMEM GlutaMax+ only, to ensure adequate cell adhesion to 
the surface of the wells, and to exclude the influence of Atorvastatin concentration 
in cell adhesion. 
After 24 hrs incubation, cell adhesion was confirmed by phase contrast transmitted 
light microscopy. All medium was aspirated, the cells were washed 3 times with PBS 
then medium was replaced with medium for experimental conditions. Colourless 
DMEM was used for experimental conditions, to prevent interference with 
colourimetric assays. Medium for experimental conditions included: Atorvastatin 
0.01, 0.1, 1, 10, 20µM, DMEM, DMSO equivalent to 10 µM (vehicle), and Atorvastatin 
10µM with 100µM Mevalonate. Cells were incubated at 37˚C, 5% CO2. Wells were 
populated at n=3 for all conditions. Data was collected at 4 time points: Day 1, Day 
3, Day 5, Day 7. 
 
Metabolic Activity of Cells Using Alamar Blue Assay 
 
The Alamar Blue assay is a well-established assay, used to assess metabolic function 
and cellular health. The assay is based upon the molecule Resazurin, a nontoxic, non-
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fluorescent, cell permeable redox indicator dye. Resazurin is continually converted 
to bright red–fluorescent Resorufin by the reduction reactions of viable, 
metabolically active cells. Following the reaction, the absorbance maxima of the 
molecule changes from 530nm to 590nm. Appropriate colourimetric techniques are 
used to quantify the response, and thereby indicate level of metabolic activity. 
 
All culture medium was aspirated from each well and transferred sequentially to 
fresh 24 well plates, to create an identical copy of the 24 well plate containing the 
cells. 500µl of the aspirated medium was then replaced into its original well, to 
maintain the same conditions as original seeding. 50µl Alamar blue (AbD Serotec, UK) 
was then added to each well. The plates were incubated at 37˚C, 5% CO2 for 4 hours. 
Following incubation, 100µl of medium containing Alamar Blue was aspirated from 
each well and transferred to black 96 well plates read using an FLx800 microplate 
fluorescence reader in conjunction with the KC Junior operating platform (BIO-TEK 
Instruments, USA). 
 
All wells of the 24 well plates containing the cells were washed 3 times with PBS, 
then immediately frozen at -85C. These steps were repeated on repeated on days 




CyQUANT Cell Proliferation Analysis 
CyQUANT cell proliferation assay (ThermoFisher Scientific) is a non-radioactive, 
sensitive method to assess cell proliferation based on DNA content. The amount of 
DNA in each cell remains constant for a given cell line or cell type; this assay can 
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therefore be used to provide an accurate and simple measure of cell number. 
CyQUANT cell proliferation assays are more sensitive than colorimetric-based assays, 
and are not radioactive and do not depend upon the metabolic status of the cell. 
 
Creation of Cell Number Standard Curve Using CyQUANT 
 
A T75 flask, with a confluent monolayer of fibroblasts confirmed by light microscopy 
was selected. All medium was aspirated, and cells were washed x3 with PBS. Cells 
were detached with 4ml 10% trypsin, for 5 minutes, with detachment confirmed 
under light microscopy. 8ml of medium was added to the flask, and the cell 
suspension was transferred into 15ml Falcon tube, and centrifuged at 1500 rpm for 
5 minutes. The supernatant was aspirated and discarded. The cell pellet was then 
resuspended in 1.3 ml PBS, and cells vortexed briefly. The cells were counted using a 
haemocytometer, showing a count of 835000 cells/ml; giving 108550 cells in total. 
The cell suspension was transferred to 1.5ml Eppendorf tube, and centrifuged in a 
microcentrifuge at 200xg for 5 minutes. The supernatant was removed and discarded 
without disturbing the cell pellet. The Eppendorf tube containing the cell pellet was 
then transferred to a freezer at -80C for 4 hours to achieve cell lysis. 
 
CyQUANT GR dye/cell lysis buffer was prepared in accordance with the 
manufacturer’s instructions (1ml cell lysis buffer, 19ml nuclease free distilled water, 
50µl CyQUANT stock solution dye). The tube containing the cell pellet was removed 
from freezer, and the pellet was allowed to thaw at room temperature. 1.0 ml 
CyQUANT GR dye/cell lysis buffer was added to thawed cell pellet, and the cells were 
resuspended by brief vortexing. A dilution series was generated within wells of 96 
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well plate, in 200µl volumes: n=4 for concentrations ranging from 0 to 50000 cells. 
The samples were protected from light and incubated at room temperature for 5 
minutes. Fluorescence was measured using a FLx800 microplate fluorescence reader 
in conjunction with the KC Junior operating platform (BIO-TEK Instruments, USA) with 
excitation and emission setting of 485/520 nm. Sensitivity was set to automatic, 
adjusted to high value wells. Values were plotted on a scatter chart with fluorescence 
on y axis and cell number on x axis. A line of best fit was added to chart, and the 
correlation coefficient generated. 
CyQUANT Assay on Cultured Cells 
 
The cells used were from the same cell line as those used for the calibration curve 
calculation. The 24 well plates which had been frozen at -80C were thawed at room 
temperature, and add 200 μL of the CyQUANT GR dye/cell-lysis buffer was added to 
each sample well.  The plates were incubated at room temperature 4 minutes, 
protected from light. 180 μL of CyQUANT reagent was aspirated from each well, and 
transferred into clean plates. Fluorescence was measured using a FLx800 microplate 
fluorescence reader in conjunction with the KC Junior operating platform (BIO-TEK 
Instruments, USA) with excitation and emission settings of 485/520 nm. Sensitivity 














The Effect of Atorvastatin on the Metabolic Activity 
And Proliferation of Primary Cultured  
















The Minitab Software (Minitab® 17.1.0) was used for the analyses. One-way ANOVA 
test was modelled to determine whether the mean values for metabolic activity and 
cell proliferation differ among the treatments (A0.01, A0.1, A1, A10, A20, Veh, Med, 
Meval) using Tukey Pairwise Comparisons method. It was assumed that the variance 
is constant across all groups and two-sided confidence interval with 95% confidence 
level was used for the analyses. Interval plots and Tukey confidence interval plots 




Cell proliferation is quantified, and represented on the graphs, by total cell number 
from the CyQuant assay, having followed the calibration curve calculation method 
described above. 
CQ 15000 (CyQUANT 15000 cells/well) 
Day 1. There was no difference in cell proliferation among A0.01, A0.1, A1, A10, and 
controls (Veh, Med, Meval). A20 resulted in significantly less cell proliferation in 
comparison to A0.01 (P<0.0001), A0.1 (P<0.0001), A1 (P=0.001), A10 (P=0.026), and 
controls [Veh (P<0.0001), Med (P<0.0001), Meval (P<0.0001)]. 
Day 3. There was no difference in cell proliferation among A0.01, A0.1, A1, and 
controls (Veh, Med, Meval). A10 and A20 resulted in significantly less cell 
proliferation in comparison to Med as control (P= 0.005 and P<0.0001, respectively). 
Day 5. A0.1 and A10 resulted in more cell proliferation in comparison with Meval as 
control (P=0.007 and P=0.003, respectively). A20 resulted in less cell proliferation in 
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comparison with A0.1 (P=0.036), A1 (P= 0.014), and Med as control (P=0.004). There 
was no difference in cell proliferation among other comparisons. 
Day 7. A0.01 resulted in significantly more cell proliferation in comparison to A10 
(P<0.0001), A20 (P<0.0001), and Meval as control (P<0.0001). A0.1 resulted in 
significantly more cell proliferation in comparison to A10 (P<0.0001), A20 (P<0.0001), 
and Meval as control (P<0.0001). A1 resulted in in significantly more cell proliferation 
in comparison to A10 (P<0.0001), A20 (P<0.0001), and Meval as control (P<0.0001). 
A10 resulted in significantly more cell proliferation in comparison to Med (P=0.002) 
and Veh as controls (P<0.0001). A20 resulted in significantly less cell proliferation in 
comparison to Med (P<0.0001) and Veh as controls (P<0.0001). 












































Interval Plot of Day 1 Cell Proliferation vs Treatment
95% CI for the Mean
The pooled standard deviation was used to calculate the intervals.
Figures to Demonstrate The Effect of Atorvastatin 
Concentration on Cell Proliferation Over 4 Time Points in a 
Densely Seeded Cell Population 
 


























































Interval Plot of Day 3 Cell Proliferation vs Treatment
95% CI for the Mean
The pooled standard deviation was used to calculate the intervals.
 





























































Interval Plot of Day 5 Cell Proliferation vs Treatment
95% CI for the Mean




















































Interval Plot of Day 7 Cell Proliferation vs Treatment
95% CI for the Mean


























CQ2500 (CyQUANT 2500 cells/well) 
Day 1. There was no difference in cell proliferation among A0.01, A0.1, A1, A10, A20 
and Meval as control. Med as control resulted in in significantly less cell proliferation 
in comparison to A0.01 (P=0.005), A0.1 (P<0.0001), A1 (P=0.002), and A10 (P=0.009). 
A0.1 resulted in significantly more cell proliferation in comparison to Veh as control 
(P=0.006). 
Day 3. A0.1 resulted in in significantly more cell proliferation in comparison to A20 
(P=0.002) and controls [Veh (P=0.026), Med (P=0.001), Meval (P=0.013)]. A1 resulted 
in significantly more cell proliferation in comparison to A20 (P=0.010 and Med as 
control (P=0.005). There was no difference in cell proliferation among other 
comparisons.  
Day 5. A0.01 resulted in significantly more cell proliferation in comparison to A10 
(P<0.0001), A20 (P<0.0001), Med as control (P<0.0001) and Meval as control 
(P<0.0001). A0.1 resulted in significantly more cell proliferation in comparison to A10 
(P<0.0001), A20 (P<0.0001), Med as control (P<0.0001) and Meval as control 
(P<0.0001). A1 resulted in significantly more cell proliferation in comparison to A10 
(P=0.003), A20 (P=0.001), Med as control (P<0.0001) and Meval as control (P=0.003). 
Veh as control resulted in significantly more cell proliferation in comparison to A1 
(P=0.011), A10 (P<0.0001), and A20 (P<0.0001). There was no difference in cell 
proliferation among other comparisons.  
Day 7. A0.01 resulted in in significantly more cell proliferation in comparison to A20 
(P=0.001) and controls [Veh (P=0.006), Med (P<0.0001), Meval (P<0.0001)]. A0.1 
resulted in in significantly more cell proliferation in comparison to Med as control 
(P=0.002) and Meval as control (P=0.006). A1 resulted in significantly more cell 
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proliferation in comparison to A20 (P=0.005) and controls [Veh (P=0.026), Med 
(P<0.0001), Meval (P<0.0001]. A10 resulted in significantly more cell proliferation in 
comparison to Med as control (P=0.009) and Meval as control (P=0.029). There was 
















































Interval Plot of Day 1 Cell Proliferation vs Treatment
95% CI for the Mean
The pooled standard deviation was used to calculate the intervals.
Figures to Demonstrate The Effect of Atorvastatin 
Concentration on Cell Proliferation Over 4 Time Points in a 
Sparsely Seeded Cell Population 
 
















































Interval Plot of Day 3 Cell Proliferation vs Treatment
95% CI for the Mean


















































Interval Plot of Day 5 Cell Proliferation vs Treatment
95% CI for the Mean



















































Interval Plot of Day 7 Cell Proliferation vs Treatment
95% CI for the Mean



























AB 15000 (Alamar Blue, 15000 cells/well) 
Day 1.  A10 and A20 resulted in significantly less metabolic activity compared with 
Med as control (P=0.010 and P<0.0001, respectively). There was no difference in 
metabolic activity among other comparisons 
Day 3. A1 resulted in significantly more metabolic activity compared with Med as 
control (P=0.027) and A20 resulted in significantly less metabolic activity compared 
with Med as control (P=0.003). There was no difference in metabolic activity among 
other comparisons. 
Day 5. A20 resulted in significantly less metabolic activity compared with A0.01 
(P=0.012), A0.1 (P=0.003), A1 (P=0.002), Med as control (P=0.001) and Veh as control 
(P=0.004). There was no difference in metabolic activity among other comparisons. 
Day 7. A0.01 resulted in in significantly more metabolic activity in comparison to A10 
(P<0.0001), A20 (P<0.0001) and Meval as control (P<0.0001). A0.1 resulted in in 
significantly more metabolic activity in comparison to A10 (P<0.0001), A20 
(P<0.0001), Med as control (P=0.002) and Meval as control (P<0.0001). A1 resulted 
in significantly more metabolic activity in comparison to A10 (P=0.007), A20 
(P<0.0001) and Meval as control (P=0.008). A10 resulted in significantly less 
metabolic activity in comparison to Veh as control (P=0.007). A20 resulted in 
significantly less metabolic activity in comparison to Med as control (P=0.001) and 






























Interval Plot of Day 1 Metbolic Activity vs Treatment
95% CI for the Mean
The pooled standard deviation was used to calculate the intervals.
Figures to Demonstrate The Effect of Atorvastatin 
Concentration on Metabolic Activity Over 4 Time Points in a 
Densely Seeded Cell Population 
 














































Interval Plot of Day 3 Metabolic Activity vs Treatment
95% CI for the Mean


















































Interval Plot of Day 5 Metabolic Activity vs Treatment
95% CI for the Mean




















































Interval Plot of Day 7 Metabolic Activity vs Treatment
95% CI for the Mean


























AB 2500 (Alamar Blue, 2500 cells/well) 
Units on the Y axes of the figures displaying metabolic activity are Absorbance. 
Numerical values were generated by the plate reader, using the settings described in 
the methods section.  
Day 1. A0.1 resulted in in significantly more metabolic activity in comparison to A1 
(P=0.027) and A20 (P=0.006). There was no difference in cell proliferation among 
other comparisons. 
Day 3. There was no difference in metabolic activity among other comparisons. 
Day 5. A0.01 resulted in in significantly more metabolic activity in comparison to A10 
(P=0.003), A20 (P=0.001), Med as control (P=0.008) and Meval as control (P=0.003). 
A0.1 resulted in in significantly more metabolic activity in comparison to A10 
(P=0.021), A20 (P=0.006), Med as control (P=0.002) and Meval as control (P=0.022). 
A1 resulted in significantly more metabolic activity in comparison to A10 (P=0.007), 
A20 (P<0.0001) and Meval as control (P=0.008). Veh as control resulted in 
significantly more metabolic activity in comparison to other treatments. There was 
no difference in metabolic activity among other comparisons. 
Day 7. A0.01 resulted in significantly more metabolic activity in comparison to A20 
(P<0.0001) and controls [Veh (P=0.003), Med (P<0.0001), Meval (P<0.0001)]. A0.1 
resulted in significantly more metabolic activity in comparison to A20 (P=0.001) and 
controls [Veh (P=0.017), Med (P<0.0001), Meval (P=0.001)]. A1 resulted in 
significantly more metabolic activity in comparison to A10 (P=0.004), A20 (P<0.0001) 
and controls [Veh (P<0.0001), Med (P<0.0001), Meval (P<0.0001)]. There was no 






























Interval Plot of Day 1 Metbolic Activity vs Treatment
95% CI for the Mean
The pooled standard deviation was used to calculate the intervals.
Figures to Demonstrate The Effect of Atorvastatin 
Concentration on Metabolic Activity Over 4 Time Points in a 
Sparsely Seeded Cell Population 
 



















































Interval Plot of Day 3 Metabolic Activity vs Treatment
95% CI for the Mean





















































Interval Plot of Day 5 Metabolic Activity vs Treatment
95% CI for the Mean






















































Interval Plot of Day 7 Metabolic Activity vs Treatment
95% CI for the Mean









































Ethical permission for this study was approved by national research ethics service 
(NRES) Committee South Central - Oxford C (Appendix 1). The study was sponsored 
by The Royal Liverpool University Hospital. Data was recorded in a prospectively 
managed database. All patients undergoing major surgery requiring an ileocolonic, 
colocolonic or colorectal anastomosis at The Royal Liverpool University Hospital 
colorectal unit, between August 2013 and September 2014 were invited to 
participate in the study. The study was clearly explained to each patient pre-
operatively, and patients were provided with literature to reinforce the details of the 
study, and with contact details of the investigators. The patients understood that 
participating in the project would have no bearing whatsoever on decisions 
surrounding the management of their disease, or on their clinical course. The 
patients also understood that they would have to make no further personal 
contribution to the study, other than the pre-operative interview. The patients all 
understood that a small amount of healthy tissue may be taken from the operative 
specimen for cell culture, and that they were entitled to withhold consent for tissue 
sampling should they wish. Those patients who agreed to participate in the study 
signed a consent form pre-operatively; every patient in the study was consented by 
the lead investigator. Following consent, pre-operative data was collected using 
Clinical Research Form A (CRF A, appendix 2). The data included patient 
demographics, medical comorbidities, current medications, smoking history, alcohol 
intake, the details of the planned operation, and the underlying disease being 
treated. Results of pre-operative blood tests, including lipid profiles, were also 
recorded. Operation notes for each patient were reviewed to confirm details of the 
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operation. Each patient’s post-operative course was analysed by reviewing the notes 
between 30- and 45-days post-operation. Patients were excluded if they had a 
defunctioning ileostomy or did not have an anastomosis created. 
Anastomotic leak was defined as a clinically suspected leak, with radiological or intra-
operative confirmation. Computed tomography (CT) scans were ordered at the 
discretion of the clinical team responsible for the patient. 
All statistical analysis was performed using dedicated statistical software (SPSS v20, 
IBM Corp, Armonk, NY, USA). All data are presented as median (Interquartile range) 
unless otherwise stated. Group comparisons were performed using Mann-Whitney 




During the study period 124 patients undergoing major surgical resection consented 
to take part in the study. Seven patients had a defunctioning ileostomy created, two 
underwent a Hartmann’s procedure and a further two patients were excluded due 
to incomplete documentation. Data from 113 patients was therefore available for 
analysis. Of the 113 procedures, 45 patients underwent right hemicolectomy, 9 
underwent left hemicolectomy, 20 underwent sigmoid colectomy, 6 underwent 
reversal of Hartmann’s procedures, 27 underwent anterior resections and 6 other 
major colorectal operations. Demographics of the patient cohort are displayed in 
Table 2, and are representative of the patient cohort served by and inner-city 
teaching hospital with a high proportion of patients from a deprived area. 
38.9% of patients were taking statins pre-operatively. Patients taking statins had 
significantly more co-morbidities than those patients not taking statins (Table 2). 
Those patients also had a significantly greater number of recognised risk factors for 
AL. 
The AL rate in our cohort was 5% (6 patients). Factors predictive of leak were 
demonstrated in Table 4. Statins had no effect on AL rates in our study, neither were 
they associated with a significant difference in maximum 7 day CRP (128mg/L (83-
206) v 142 (85-238), p=0.697). The nature of the operation, and therefore 
anastomotic site, was not associated with AL in our study (p=0.269). Factors found 
to be significantly associated with anastomotic leak in our study were impaired renal 
function, measured by low pre-operative eGFR, and maximum 7 day CRP.  
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Multivariate regression was not performed due to the low numbers of AL 
encountered. 
Descriptor Cohort 
Age 67 (57-75) 
Male Sex 62 (54%) 
Body Mass index (BMI) 26.9 (23.4-30.6) 
Smoking 













Chronic Kidney Disease 3 (2.7%) 
Ischaemic Heart Disease 14 (12.4%) 
Hypertension 39 (34.5%) 
Diabetes 26 (23.2%) 
Statin USe 44 (38.9%) 
Antiplatelet Use 33 (29.2%) 










Descriptor Statins No Statins p value 
Age 73 (66-76) 61 (49-70) <0.001* 
Male Sex 26 (59.1%) 36 (52.2%) 0.471 
Body Mass index (BMI) 27.8 (24-33) 25.8 (23-30) 0.148 
Operation for 
malignancy 
34 (77.3%) 36 (52.2%) 0.007* 
Pre-operative 
radiotherapy 




13 (30.2%) 26 (41.9%) 
0.01* Current 
Smoker 
27 (62.8%) 22 (35.5%) 
Ex Smoker 3 (7%) 14 (22.9%) 
ASA Score 
1 2 (4.7%) 24 (37.5%) 
<0.001* 
2 28 (65.1%) 34 (53.1%) 
3 11 (25.6%) 6 (9.4%) 
4 2 (4.7%) 0 
Chronic Kidney Disease 1 (2.3%) 2 (2.9%) 1 
Ischaemic Heart Disease 11 (25%) 3 (4.3%) 0.002* 
Hypertension 27 (61.4%) 12 (17.4%) <0.001* 
Diabetes 17 (38.6%) 9 (13.2%) 0.003* 
Antiplatelet Use 24 (54.5%) 9 (13.4%) <0.001* 
Haemoglobin (g/L) 123.5 (112-136) 133 (119.5-142) 0.015* 
White cell count (109/L) 8 (6-10) 7 (6-9.5) 0.335 
Albumin (g/L) 42 (39.3-44) 43 (40.3 – 45) 0.110 
eGFR (mL/min/1.73m2) 70 (54.5-85) 80 (40.24 – 45) 0.001* 
Total cholesterol 
(mmol/L) 
4 (3-4) 5 (4-5) <0.001* 
Triglycerides (mmol/L) 1 (1-2) 1 (1-2) 0.584 
HDL (mmol/L) 1 (1-2) 1 (1-2) 0.239 
LDL (mmol/L) 2 (1-2) 3 (2-3) <0.001* 
Table 3: Summary of demographics and recognised risk factors for anastomotic leak 
amongst the clinical study population, comparing those patients taking statins, and 
those patients not taking statins at the time of surgery. 
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Descriptor Leak No Leak p value 
Age 57 (50-75) 67 (58-75) 0.493 




3 (50%) 36 (36.4%) 
0.856 Current 
Smoker 
2 (33.3%) 47 (47.5%) 
Ex-Smoker 1 (16.7%) 16 (16.2%) 
ASA Score 
1 1 (16.7%) 25 (24.8%) 
1 
2 4 (66.7%) 58 (57.4%) 
3 1 (16.7%) 16 (15.8%) 
4 0 2 (2%) 
Chronic Kidney Disease 0 3 (2.8%) 1 
Ischaemic Heart Disease 1 (16.7%) 13 (12.1%) 0.557 
Hypertension 1 (16.7%) 38 (35.5%) 0.663 
Diabetes 1 (16.7%) 25 (23.6%) 1 
Pre-operative 
radiotherapy 
2 (33.3%) 8 (7.5%) 0.089 
Malignancy 6 (100%) 64(59.8%) 0.081 
Antiplatelet Use 2 (33.3%) 31 (29.5%) 1 
Statin Use 3 (50%) 41 (45.8%) 0.676 
Haemoglobin (g/L) 115 (105-144) 131 (117-141) 0.327 
White cell count (109/L) 9.5 (6.8-14) 8 (6-10) 0.127 
Albumin (g/L) 41.4 (35.8-43.3) 43 (50-45) 0.207 
eGFR (mL/min/1.73m2) 60.5 (35.75-72) 78 (65-89) 0.019* 
Total cholesterol 
(mmol/L) 
4 (2.75-4.5) 4 (4-5) 0.265 
Triglycerides (mmol/L) 1 (1-1.25) 1 (1-2) 0.256 
HDL (mmol/L) 1 (1-2) 1 (1-2) 0.605 
LDL (mmol/L) 2 (1-3) 2 (2-3) 0.526 
Max 7 Day CRP 258 (217-377) 126 (83-208) 0.003* 
Table 4: Summary of demographics and recognised risk factors for anastomotic leak 
amongst the clinical study population, comparing the patients who were diagnosed 






























The effect of statins on primary cultured human colonic myofibroblasts 
 
The early part of the laboratory work was dedicated to learning and refining a 
reproducible method for primary cell culture from specimens of healthy human 
colon, harvested at the time of surgery, then ensuring that adequate numbers of 
early passage cells could be grown and maintained. Using primary patient derived 
cells in research is one of the most challenging parts of cell biology and in vitro cell 
culture.  It is absolutely, rightly valued as the most relevant research that can be 
conducted outside of a body.  As myofibroblasts are the main secretors of 
extracellular matrix, they drive the restoration of tissue integrity after injury(118). 
Myofibroblasts are fundamental to tissue healing from the very earliest stages of the 
process, therefore it is plausible that any factor that may influence their function and 
proliferation could promote, or impair, tissue healing. 
 
As described earlier in this thesis, there is early evidence to suggest that patients 
taking statins may have a reduced incidence of anastomotic leak following colorectal 
surgery. Although statins are widely used to reduce serum cholesterol levels in 
patients believed to be at high risk of cardiovascular disease, they are recognised to 
have pleiotropic effects; effects which influence tissue healing. A number of statins 
are in widespread use throughout the developed world, and most of these 
compounds are available for use in in vitro work. Atorvastatin was chosen for this 
study as it remains stable in a stock solution, and can be reliably dissolved in a non-
toxic concentration of dimethyl sulfoxide (DMSO) (referred to as vehicle). Unlike 
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Simvastatin, Atorvastatin does not require extra steps to activate it in cell medium. 
In accordance with other in vitro studies that have investigated the effects of statins 
on cell function, a range of concentrations was created, to include sub-therapeutic 
and supra-therapeutic levels, in addition to therapeutic equivalent concentrations. 
This range is particularly important in the study of statins, as a non-linear, biphasic 
effect is often observed (as described in the introduction). The effect of the 
interventions was compared to control conditions: plain medium, medium 
containing DMSO at the same concentration as that used to make the stock 
Atorvastatin solution, and medium containing both Atorvastatin and mevalonate, to 
consider whether any effects observed were due to inhibition of the mevalonate 
pathway, or were independent of that pathway. 
 
Effect of Atorvastatin on Cellular Metabolism 
 
The influence of Atorvastatin on metabolic activity of primary cultured human 
colonic myofibroblasts was assessed using Alamar Blue, with wells seeded at low cell 
density and high cell density. For both densities a non-linear relationship is observed, 
with the considerable inhibition of metabolic activity being associated with higher 
concentrations of Atorvastatin. Increased metabolic activity was seen at lower 
concentrations, although concentrations in the middle of the range promoted the 
greatest level of metabolic activity, which is consistent with other in vitro work 
described in the introduction. The observation that the lowest level of metabolic 
activity is seen with the higher concentrations of Atorvastatin is seen across all days, 
and over both densely seeded and sparsely seeded conditions. The observation that 
lower doses of statins promote increased metabolic activity compared to control 
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conditions is particularly interesting; such an effect in vitro may ultimately have 
clinical relevance in the use of statins to promote tissue healing. The effect of the 
higher concentrations may simply reflect a toxic effect of Atorvastatin at these 
concentrations. 
 
Effect of Atorvastatin on Cell Proliferation 
 
As previously described, cell proliferation over time was measured using the 
CyQUANT assay. This data was generated from the same cell populations that were 
analysed for the Alamar Blue metabolic activity assay. A very similar trend to that 
observed in metabolic activity is seen in this study, with the lower responses being 
seen at higher concentrations, again suggesting an inhibitory effect of Atorvastatin 
at higher concentrations. Although the effect is similar to that seen with the assay of 
metabolic activity, the effect of variation in concentration of Atorvastatin on cell 
proliferation is less pronounced than the effect on metabolic activity.  
 
Comparing the effects observed in the Alamar Blue and CyQUANT studies, it is seen 
that metabolism is more obviously affected than proliferation, with a more 
pronounced non-linear relationship. This suggests that Atorvastatin is promoting 
intracellular activity, and not having its effect by promoting cell proliferation. For 
both Alamar blue and CyQUANT studies, the control groups were considered 
together, as there was no significant difference between them. In both studies, the 
outcomes from the control condition of Atorvastatin and mevalonate were the same 
as Atorvastatin only; mevalonate therefore did not reverse the influence of 
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Atorvastatin, indicating that the effects are independent of the mevalonate 
(cholesterol synthesis) pathway. 
 
Direction for Future Studies 
 
Primary derived myofibroblasts were utilised for this study, as they are amongst the 
first cells to respond to tissue injury, and to promote repair by secreting extracellular 
matrix. To the author’s knowledge this is the first study to investigate the effect of 
statins on cells that have been cultured from fresh specimens derived from human 
colon. This study, simply from the success of doing that, has demonstrated that it is 
a feasible model which has the potential to form the basis of valuable non-animal, 
primary human cell research. Future research could include investigating other 
markers of myofibroblast function and ECM secretion, including collagen secretion 
into the cell medium. The use of multiplex enzyme-linked immunosorbent assay 
(ELISA) panels would allow simultaneous assays of a range of matrix 
metalloproteinases (MMP), and would represent a valuable approach to adding 
more detail into the knowledge obtained. Future research could also investigate the 
function of other cell types fundamental to tissue healing, such as microvascular 
endothelial cells, macrophages and the sub types of macrophages, as these sub 
populations and their predominance and role in inflammation and wound healing are 
the subject of much research relating to skin wound healing. 
 
In future research, the laboratory research could be linked to the clinical course of 
the donor patients; it would then be possible to identify whether differences in cell 
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function and ECM secretion were associated with the risks of complications, 
specifically anastomotic leak. 
 
Clinical Study Discussion 
The beneficial effects of perioperative statin use have been demonstrated in cardiac 
and vascular surgery, but have only been investigated to a much lesser extent in 
other specialities. As already described, there is conflicting data regarding the 
influence of statins upon outcomes in major colorectal surgery, particularly regarding 
AL. 
This study has not demonstrated an overall reduction in AL risk in patients taking 
statins. An important observation, however, is that patients taking statins had a 
greater burden of co-morbidities and AL risk factors than those not taking statin 
therapy, even so, they did not demonstrate the expected higher incidence of AL. That 
observation has also been shown in other retrospective reviews of major colorectal 
practice. It is therefore reasonable to suggest that statin therapy might reduce the 
risk of AL in these high-risk patients; statin use may effectively be a form of 
pharmacological prehabilitation. That observation is particularly pertinent to the 
cohort of patients in this study. The Royal Liverpool University Hospital serves a 
socioeconomically deprived population, with many patients having a variety of 
comorbidities. Although specific deprivation data was not collected during this study, 
The English Indices of Deprivation, a report produced by the Department for 
Communities and Local Government, showed that at the time of data collection for 
this study, 45% of neighbourhoods within the local authority district of Liverpool 
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were in the most deprived 10% of neighbourhoods nationally(119). The 2016 Health 
Survey for England found that 14% of adults were prescribed lipid lowering 
medication whereas 38.9% of the patients in this study was prescribed a statin. The 
difference is likely to reflect both a relatively unhealthy population, but also the 
diligence of the local primary care services in ensuring that appropriate primary and 
secondary prevention of cardiovascular disease is addressed. 
As discussed earlier in this document, there are many proposed pre-operative risk 
factors, and peri-operative clinical findings believed to be associated with an 
increased risk or incidence of leak, however very few are robustly demonstrated. In 
this study, only two of the measured values were significant; a low eGFR, reflecting 
poor renal function, and a high CRP level 7 days post-operatively. Both of these 
factors have been shown to be associated with an increased incidence of AL in 
previous studies, so those observations in this study can be interpreted as validating 
the model and the method of the study.  
In this study, a number of risk factors for AL identified in other studies, were not 
shown to be associated with AL in this study. Particularly significant risk factors not 
associated with AL in this study include smoking, diabetes and obesity, as these have 
frequently been identified as risk factors in other studies. It is likely that the relatively 
small patient population, and low number of leaks accounts for these observations. 
It is widely accepted that AL is a multifactorial entity, moreover, leaks will occur in 
patients with either no, or very few, obvious risk factors, whilst some patients with 
several risk factors will not experience leak. For those reasons, it is extremely 
challenging to identify individual risk factors for AL. 
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Limitations of the Study and Direction of Future Research 
This study has the inherent limitations of a retrospective study, carried out in a single 
centre with a population that may not be representative of the wider society. AL was 
diagnosed based on radiological or operative confirmation of a clinically suspected 
AL; although some small leaks may have been undetected, the definition used in this 
study is conventional in observational studies investigating AL. The small number of 
patients in the study, and small number of ALs reported and the effect this has on 
the power of our study is also acknowledged. The decision to exclude patient with a 
defunctioning stoma may have also influenced the findings of the study, as low 
anterior resections are recognised as having a higher incidence of AL. This group was 
excluded as anastomotic deficiency in defunctioned patients is often not recognised 
until the anastomosis is investigated radiologically or clinically prior to planning a 
closure of stoma. As time to stoma reversal is variable, and frequently several 
months, follow-up for these patients may well have fallen outside of the data 
collection period. 
The limitations of this study may be borne in mind when considering future study 
design. Designing a randomised controlled trial to investigate the relationship 
between statins and leak risk would be highly compromised, as this would rely on 
either recruiting patients with no indications for statins, or denying patients with an 
indication for statins the appropriate medication. It would also be necessary to 
control for other recognised risk factors for leak, so would require a study population 
of tens of thousands. Snapshot studies and registries are likely to represent the most 
realistic way of investigating a relationship between AL and statin use. The European 
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Society of Coloproctology (ESCP) collaborative group snapshot audit of right 
hemicolectomy recruited 3208 patients within a 2-month period, and the subsequent 
left sided resection audit recruited 3676 patients within a 10-week period(120, 121). 
Such an extensive multicentre approach is a valid way to collect the volume of data 
required to investigate problems with a complex multifactorial aetiology. The 
American College of Surgeons’ National Surgical Quality Improvement Program 
(NSQIP) is a validated, outcomes-based program designed to measure and improve 
quality of surgical care. This is essentially a prospectively maintained rolling audit 
programme, and collects vast amounts of data from every patient treated in the 
institutions enrolled into the program, and it is possible that further research into 
the relationship between statins and leak may be conducted through the ACS NSQIP. 
Beyond the consideration of statins, this observation emphasises the potential 
importance of optimal management of comorbidities in the preoperative phase, in 
order to mitigate against the risk of complications associated with comorbidities. This 
study also raises the broader issue of considering the influence of the co-morbidities 
and pre-operative medication taken by patients undergoing colorectal surgery; this 
is an under investigated issue. Two recent comprehensive and authoritative reviews 
of the challenges presented by anastomotic leaks, and strategies to minimise the 
incidence have been published(122, 123). Both reviews highlight areas for future 
research, yet neither mentions assessment of the patient’s current medications.  
In conclusion we have demonstrated that patients taking statins had more 
comorbidities than those not taking statins, but those patients did not demonstrate 
the higher anastomotic leak rate that might have been expected. Further studies 
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should be directed towards identifying whether statins do indeed modify the risk of 
AL, and indeed other perioperative complications in high-risk patients. As many high-
risk patients will already be taking statins, and low-risk patients may be unlikely to 
derive a benefit from statins, an RCT is unlikely to be an ethically acceptable study 
design, therefore a prospectively held multi-centre registry would be the most 
appropriate method of investigation, and would also provide the opportunity to 
investigate the effect of other medications upon perioperative outcomes. 
Conclusions 
 
Anastomotic leak remains one of the most devastating complications of colorectal 
surgery; efforts to reduce the incidence of this complication are therefore 
paramount. These laboratory and clinical studies were designed and conducted to 
further investigate the suggested relationship between statins and anastomotic leak; 
specifically, that those patients taking statins may have a reduced risk of anastomotic 
leak. To the author’s knowledge, this is the first study to investigate the effects of 
statins on primary cultured cells, from fresh specimens of human colon. This research 
experimentally evidenced an effect of Atorvastatin upon the metabolic activity of 
colonic myofibroblasts. The method of isolating and culturing primary human 
myofibroblasts was developed and could now be repeated and provided as a 
reproducible technique, and provides a valuable human cell model for further 
research. 
 
Anastomotic leak is widely accepted to be a multifactorial entity, therefore reducing 
the incidence of leak will require multiple risk factors to be addressed. It is certainly 
not the suggestion of this author that statins, or any other single medication, will 
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represent a mechanism to prevent AL. However, medications such as statins, that are 
shown to promote tissue healing may have a role in limiting complications such as 
leaks, especially for those patients with a high risk of anastomotic leak, due to 
comorbidities such as underlying cardiovascular disease. 
 
The clinical study that was run in parallel to the laboratory work was based upon 
prospectively collected data, to investigate both potential effects of statins, and also 
to allow other risk factors to be considered. Although statins were not shown to 
reduce the risk of AL, there was no observed increased incidence of AL in high-risk 
individuals with comorbidities. The number of patients that is required to elucidate 
the effect of a single risk factor or intervention in an entity as complex as AL is much 
higher than could be collected in a single centre over 12-18 months. Data from 
randomised controlled trials is regarded as being the most robust data to direct 
change in clinical practice. It is unlikely that an RCT would be an appropriate method 
to investigate the relationship between statins and AL, as a scientifically robust 
version of that study would require patients who depend on statins being denied that 
medication, and would therefore not be ethically acceptable. This highlights the 
importance of the “big-data” approach, and it is therefore likely that studies such as 
the ESCP snapshot studies, or studies delivered from the ACS NSQIP will represent 
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CRF A- Demographic Data and Preoperative Assessment 
For patients undergoing elective colorectal resection 
Patient Information 
 
                                       
RPatient Name 
     
 
D.O.B:                                                                                                      ESTIMATED DATE OF OPERATION: ……./……../…….. 
Hospital 
Number: 
    dd      mm       yyyyy 
Consultant:                                                                                                       DATE OF THIS ASSESSMENT:  ……./……../…….. 
             dd      mm    yyyyy 
          
 




Gender    Male   Female  
 





Smoker?                  Never smoked  Ex-smoker          Current smoker    
          (when stopped? ......)                (Pack years……......) 
       (20/day for a yr = 1 pack yr)  
 
Alcohol                  Non Drinker  <10 units/wk         10-30 units/wk   
>30units/wk   
    1 unit = 1 bottle of beer, 1 glass of wine or 1 measure of spirits.  
 





Taking a Statin  NO         YES  
If Yes, Dose, name of statin and duration of 
therapy__________________________________ 
 
Taking an Antiplatelet NO         YES  














CRF A- Demographic Data and Preoperative Assessment (continued) 
 
On Steroids or Immunosuppressed NO          YES    
within past 6 months?  Indication and duration ……………………....... 
     
Drug + dose ..................... 
 
 
Radiotherapy and chemotherapy history: 
 
 
Pre-op Radiotherapy?  NO          YES  





Pre-op Chemotherapy?  NO          YES  























Appendix 3: Clinical Research Form B 
 
CRF B. Intra-Operative Data 
 
 
Study Number:        
 
 
Date:     
 
 
Operation:         
 
 
Consultant:         
 
 
Tissue Collected:        











The Royal Liverpool and 




Department of General Surgery 
Colonic Tissue and Blood Sample Collection 
 
PATIENT CONSENT FORM 
 
 
Name of Researcher: ______________________________________ 
 
 
I confirm that I have read and understood the patient information sheet dated June 
2013 (Version 1.4) for Surplus Colonic Tissue Samples and Analysis. I have had the 
opportunity to ask questions and have had these answered satisfactorily. 
 
I understand that my participation in this project is entirely voluntary and that I may 
withdraw at any time without needing to give a reason, and without my medical care 
or legal rights being affected. 
 
I understand that sections of my medical notes may be looked at by responsible 
individuals involved in this research or from regulatory authorities where it is relevant 
to my taking part in this research. I give permission for these individuals to have access 
to my medical records. 
  
I give permission for the samples of my blood and bowel to be used for this project. 
 
I am happy for the future publication and dissemination of research involving my 
gifted sample, which may contain genetic information 
 
I agree to take part in the above study. 
 
Who has reviewed this study? 
All NHS research is reviewed by an independent group of people called a research 
ethics committee. This study was reviewed and approved by the Health Research 
Authority Oxford C committee. 
 
 
Patient Name  Signature  Date 
 
 
    
Name of Researcher  Signature  Date 
Name of person taking 
consent (if different) 
 Signature  Date 
 
When completed: 1 for patient, 1 in medical notes, 1 (original) for researcher site file 
Appendix 4: Patient Consent Form 
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Statins and colonic healing 















Chief Investigator     Principal Investigator 
 
Mr Paul Rooney    Mr Christopher Battersby 
Consultant Surgeon    General Surgical and Research 
Registrar 
Royal Liverpool University Hospital Royal Liverpool University Hospital 
Prescot Street    Prescot Street 
Liverpool     Liverpool 





The Purpose of this Form 
 
This form will help you decide if you want to participate in the research study. As you 
read this form, the Principal Investigator (the person in charge of this research) or a 
member of the research team will describe this study to you and answer all of your 
questions. You should have all your questions answered before you give your 
permission to be in the study. We encourage you to take time to discuss this with 
your family and friends.  
If you do want to be in the study, you will need to sign this form to give your consent. 
This is called informed consent form because it informs you before you sign to give 









Appendix 5: Patient Information Sheet 
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Why have I been invited to take part? 
You are being asked to be in this research study because you need to have surgery 
to remove part of your bowel. You are being asked to allow the researchers to carry 
out a small number of extra tests on the bowel tissue that is removed at the time of 
your operation. The researchers are investigating whether medications that are 
commonly taken by patients, for other conditions, have any effect upon tissue 
healing in the bowel. The researchers may also request a sample of blood to analyse 
cholesterol levels. 
The bowel that is removed will undergo all of the standard investigations, and almost 
all of the extra investigations for the purpose of research will carried out after the 
standard routine investigations are complete. We will not be taking samples of 
cancer tissue. 
 
What will happen to me if I take part in the study? 
Whether you decide to participate in this study or not, will make no difference to 
your medical care. Information about you and your disease will be recorded. This 
information includes height, weight, age, race, smoking and alcohol consumption, 
the kind of disease you have and medications you are taking. Your planned operation, 
and post-operative care will be identical whether you participate or not. The only 
difference will be that a small number of extra investigations will be carried out on 
the tissue that has already been removed. Researchers who have no involvement in 
your clinical care will not be given your name, or any details that would enable them 
to find out who the sample is from.  
The principal investigator will review your hospital notes at some point (1-2 months) 
after your operation to assess your post-operative recovery. This will not require any 
further input from you or your family. 
 
Do I have to take part in the study? 
No. If you decide not to take part, you will receive exactly the same level of care. 
 
Who can take part? 
Anyone who is being considered for planned surgery to remove a section of large 
bowel will be allowed to take part. 
 
What will happen to my sample? 
The section of bowel that is removed will be sent to the pathology laboratory, and 
analysed according to standard practice. The researchers will then carry out the extra 
tests on remaining tissue. Any remaining tissue will be stored in the histopathology 
laboratory, in the standard manner. If there is any leftover tissue not used in this 
project, it will be stored and may be used in other projects in the future without your 
knowledge. The researchers might ask to take a small sample of normal bowel tissue 
before it is sent to the laboratory. This will be done in the operating theatre, at the 
same time as the operation, and will not in any way affect the nature of the 
operation, the analysis of the sample, or your post-operative care. Any samples that 
are taken at the time of the operation (fresh tissue) will be disposed of safely at the 
end of the experiment, and will not be stored in a laboratory for future use. 
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How will my sample be anonymised? 
When your sample is transferred from the operating theatre, it will be labelled with 
a study number. There will be no way for the scientists to find out who the sample 
came from. 
 
What are the benefits of donating my sample to this study? 
There will be no direct benefit to you for participating in this study. The findings 
from this study may benefit other patients in the future. 
 
What are the risks of taking part in this study? 
Deciding to take part in the study will make no difference to what happens to you 
during your operation and hospital stay and so there are no risks to taking part in 
the study. 
 
Will I find out the results of research performed on my sample? 
You will not receive the results of research performed on your samples.  
 
How will my personal information be shared? 
We are asking for your permission to gather information about you for this study.  
This information will include personal information such as name and age. It will also 
contain information about height, weight, your medical history, information about 
medicines you take, how much you smoke and how much alcohol you drink. When 
your sample is released to researchers, your name will be removed and replaced by 
a sample number. There will be no way to connect this sample number with you. 
 
What if I change my mind after I’ve donated a sample? 
If you decide that your tissue may be kept for research, but later change your mind, 
contact any member of the research team at any time. You will be under the 
continued care of your surgeon, and can contact them to discuss withdrawing your 
consent.  
 
Will I be paid for donating my sample? 
You will not be paid to donate your sample.  
 
Who is organising this study? 
The study is organised and run by scientists and doctors from the University of 
Liverpool and Royal Liverpool University Hospital.  
 
Who can I ask for advice on whether to take part? 
We recommend that you speak to your friends and family before you decide whether 
or not to take part in this study. You can also ask to speak to a surgeon who is not 
involved in the study to get independent advice on whether to take part. If you would 
like to speak to someone independent, please ask your doctor. 
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For further specific information about this study please contact Mr Christopher 





What if I have a complaint about the study? 
 
If you are not happy with the general care and treatment you receive during the 
study, please speak first to your study doctor who will try to resolve the problem. 
They can tell you about the hospital’s standard complaints procedure in case you 
wish to take the matter further. You can do this by contacting Royal Liverpool 
University Hospital Patient Advice and Liason Service (PALS). 
 
You may also report a concern about a study or ask questions about your rights as a 
research subject by contacting the Research Ethics Committee. When you call  
with a concern, please give as much information as you can. Include the name of the 
study leader and details about the problem. This will help officials look into your 
concern. When reporting a concern, you do not have to give your name. 
 
 
 
